New perspectives on controlling progression of severe rheumatoid arthritis - A summary of the potential role of cyclosporin

Revmatologiia

Volumn 35, Issue SUPPL. 2, 1996, Pages 1-3

  Emery, P ^a   Van De Putte, L B A ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOMODULATING AGENT; INTERLEUKIN 1; METHOTREXATE;

DISEASE ACTIVITY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; T LYMPHOCYTE;

ARTHRITIS, RHEUMATOID; CYCLOSPORINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS;

EID: 0029797336     PISSN: 13100505     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_2.1     Document Type: Article

References (15)

1. Emery P. Early rheumatoid arthritis: therapeutic strategies. Scan J Rheumatol 1994;23(suppl. 100):3-7.
2. Young A, Cox N, Dixie J et al. Early rheumatoid arthritis study (ERAS). Report of first 506 patients. Arthritis Rheum 1991;34:483.
3. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984;43:8-17.
4. van Riel PLCM, van Gestel AM, van de Putte LBA. Steps towards an international consensus on prognostic markers: development and validation of response criteria in rheumatoid arthritis. Br J Rheumatol 1996;35(suppl. 2): 4-7.
5. Ferraccioli GF, Delia Casa-Alberighi O, Marubini E, Priolo F, Mathieu A, Fantini F, Cutolo M, Pasero G on behalf of GRISAR. Is the control of disease progression within our grasp? Review of the GRISAR study. Br J Rheumatol 1996;35(suppl. 2):8-13.
6. Yocum DE. Combination therapy with cyclosporin in rheumatoid arthritis. Br J Rheumatol 1996;35(suppl. 2): 19-23.
7. Scott DL, Houssein DA. Joint assessment in rheumatoid arthritis. Br J Rheumatol 1996;35(suppl. 2):14-18.
8. Gregerson PK, Silber J, Wrichester RJ. The shared epitope hypothesis. Arthritis Rheum 1987;30:1205-13.
9. Emery P, Salmon M, Bradley H et al. Genetically determined factors as predictors of radiological changes in patients with early symmetrical arthritis. Br Med J 1992;305:1387-9.
10. Gough A, Faint J, Salmon M, Bacon P, Emery P. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994;38:1166-70.
11. Roubenoff R, Kahagias J, Cannon J et al. Body cell mass and elevated IL-l-α and TNF-α in RA. Arthritis Rheum 1992;35:46.
12. A Special Report. Role of combination therapy in RA: a roundtable discussion. Rheumatology 1994;9:1-6.
13. Brahn E, Peacock DJ, Banquerigo ML. Suppression of collagen-induced arthritis by combination cyclosporin A and methotrexate therapy. Arthritis Rheum 1991;34:1282-8.
14. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
15. Rodríguez F, Krayenbühl JC, Harrision WB et al. Renal biospy findings and follow-up of renal function from rheumatoid arthritis patients treated with cyclosporin A: an update from the International Kidney Biopsy Registry. Arthritis Rheum 1996 in press.